A Phase 1/2 Study of OBX-115 Cell Therapy and Acetazolamide in People With Advanced Melanoma or Lung Cancer

Full Title

A Phase 1/2, Open-Label Study to Investigate the Safety and Efficacy of Membrane Bound IL-15 Expressing Tumor-Infiltrating Lymphocytes (OBX-115) In Participants with Advanced Solid Tumors

Purpose

The purpose of this study is to assess OBX-115 cellular therapy for people with advanced melanoma or lung cancer. The people in this study have melanoma or non-small cell lung cancer (NSCLC). Their cancers have metastasized (spread) or are inoperable (cannot be taken out with surgery) and keep growing even after treatment.

OBX-115 is a personalized cellular therapy that will be made specifically for each participant. It is a form of tumor-infiltrating lymphocyte (TIL) therapy. We will collect a sample of cells from your tumor and send it to a laboratory. There the cells will be genetically modified (changed) to make OBX-115. This treatment is designed to activate and train your immune system to find and kill cancer cells.

Acetazolamide is a drug that can enter cells easily because of its small size. Giving acetazolamide with OBX-115 may help OBX-115 find and kill cancer cells. OBX-115 is given intravenously (by vein) and acetazolamide is taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr.  Alexander Shoushtari’s office at 646-888-4161.